Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64.
PubMed
Google Scholar
Naghavi M, et al. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1151–210.
Google Scholar
Sun F, et al. LncRNA KCNQ1OT1 attenuates sepsis-induced myocardial injury via regulating miR-192-5p/XIAP axis. Exp Biol Med. 2020;245(7):620–30.
CAS
Google Scholar
Kostakou PM, et al. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology. New York: Springer; 2019. p. 91–100.
Google Scholar
Thavendiranathan P, et al. Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study. J Clin Oncol. 2016;34:2239–46.
PubMed
Google Scholar
Lefkopoulos D, Diallo I. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer article. J Clin Oncol. 2010;28(8):1308–15.
PubMed
Google Scholar
Zhang CL, et al. Stem cells in cancer therapy: opportunities and challenges. Oncotarget. 2017;8(43):75756–66.
PubMed
PubMed Central
Google Scholar
Van Acker HH, et al. Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials. Pharmacol Ther. 2016;158:24–40.
PubMed
Google Scholar
Tocchetti CG, Galdiero MR, Varricchi G. Cardiac toxicity in patients treated with immune checkpoint inhibitors: it is now time for cardio-immuno-oncology. J Am College Cardiol. 2018;71:1765–7.
Google Scholar
Sparreboom A, Verweij J. Advances in cancer therapeutics. Clin Pharmacol Ther. 2009;85(2):113–7.
CAS
PubMed
Google Scholar
Herrmann J, et al. Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation. 2016;133:1272–89.
CAS
PubMed
PubMed Central
Google Scholar
Leger KJ, et al. Circulating microRNAs: potential markers of cardiotoxicity in children and young adults treated with anthracycline chemotherapy. J Am Heart Assoc. 2017;6: e004653.
PubMed
PubMed Central
Google Scholar
Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy. J Am Coll Cardiol. 2009;53(24):2231–47.
CAS
PubMed
Google Scholar
Burridge PW, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016;22(5):547–56.
CAS
PubMed
PubMed Central
Google Scholar
Kumari H, Huang W-H, Chan MWY. Review on the role of epigenetic modifications in doxorubicin-induced cardiotoxicity. Front Cardiovasc Med. 2020;7:56.
CAS
PubMed
PubMed Central
Google Scholar
Zhou S, Palmeira CM, Wallace KB. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett. 2001;121(3):151–7.
CAS
PubMed
Google Scholar
L’Ecuyer T, et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol. 2006;291(3):H1273–80.
CAS
PubMed
Google Scholar
Dong J, Chen H. Cardiotoxicity of anticancer therapeutics. Front Cardiovasc Med. 2018;5:9.
PubMed
PubMed Central
Google Scholar
McGowan JV, et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63–75.
CAS
PubMed
PubMed Central
Google Scholar
Chaar M, Kamta J, Ait-Oudhia S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. Onco Targets Ther. 2018;11:6227.
CAS
PubMed
PubMed Central
Google Scholar
Qiao X, et al. Uncoupling DNA damage from chromatin damage to detoxify doxorubicin. Proc Natl Acad Sci USA. 2020;117(26):15182–92.
CAS
PubMed
PubMed Central
Google Scholar
Zhang Y-W, et al. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp. 2009;57:435–45.
CAS
Google Scholar
Cardinale D, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–8.
CAS
PubMed
Google Scholar
Octavia Y, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52:1213–25.
CAS
PubMed
Google Scholar
Xin H, Liu XH, Zhu YZ. Herba leonurine attenuates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells. Eur J Pharmacol. 2009;612:75–9.
CAS
PubMed
Google Scholar
Fernandez-Chas M, Curtis MJ, Niederer SA. Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model. Br J Pharmacol. 2018;175(5):763–81.
CAS
PubMed
PubMed Central
Google Scholar
Lakhani HV, Pillai SS, Zehra M, Dao B, Tirona MT, Thompson E, Sodhi K. Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer. Sci Rep. 2021;11(1):1–1.
Google Scholar
Aali E, et al. Cardioprotective effects of mebudipine in a rat model of doxorubicin-induced heart failure. Iran J Med Sci. 2020;46(2):136.
Google Scholar
Nanasi P Jr, et al. Doxorubicin induces large-scale and differential H2A and H2B redistribution in live cells. PLoS ONE. 2020;15(4): e0231223.
CAS
PubMed
PubMed Central
Google Scholar
Davies KJA, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem. 1986;261(7):3060–7.
CAS
PubMed
Google Scholar
Qin Y, et al. The role of iron in doxorubicin-induced cardiotoxicity: recent advances and implication for drug delivery. J Mater Chem B. 2021;9(24):4793–803.
CAS
PubMed
Google Scholar
Yarmohammadi F, et al. Endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity may be therapeutically targeted by natural and chemical compounds: a review. Pharmacol Res. 2021;164: 105383.
CAS
PubMed
Google Scholar
Guo JJ, et al. Alginate oligosaccharide prevents acute doxorubicin cardiotoxicity by suppressing oxidative stress and endoplasmic reticulum-mediated apoptosis. Mar Drugs. 2016;14(12):231.
PubMed Central
Google Scholar
Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12(4):339.
CAS
PubMed
PubMed Central
Google Scholar
Arai M, et al. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol. 1998;30(2):243–54.
CAS
PubMed
Google Scholar
Pecoraro M, et al. Cardiotoxic effects of short-term doxorubicin administration: involvement of connexin 43 in calcium impairment. Int J Mol Sci. 2017;18(10):2121.
PubMed Central
Google Scholar
Chang WT, et al. The early predictive value of right ventricular strain in epirubicin-induced cardiotoxicity in patients with breast cancer. Acta Cardiol Sin. 2016;32(5):550.
PubMed
PubMed Central
Google Scholar
Peng J, et al. Identification of differential gene expression related to epirubicin-induced cardiomyopathy in breast cancer patients. Hum Exp Toxicol. 2020;39(4):393–401.
CAS
PubMed
Google Scholar
Al-Kuraishy HM, Al-Gareeb AI. Potential effects of pomegranate on lipid peroxidation and pro-inflammatory changes in daunorubicin-induced cardiotoxicity in rats. Int J Prev Med. 2016. https://doi.org/10.4103/2008-7802.184314.
Article
PubMed
PubMed Central
Google Scholar
Kalender S, et al. Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats. Braz J Med Biol Res. 2002;35(11):1379–87.
CAS
PubMed
Google Scholar
Pophali PA, Patnaik MM. The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. 2016;22:40.
CAS
PubMed
PubMed Central
Google Scholar
Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210.
CAS
PubMed
PubMed Central
Google Scholar
El-Dabh A, Acharya D. Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. Pulm Circ. 2019;9(3):2045894019865704.
PubMed Central
Google Scholar
Porta-Sánchez A, et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc. 2017;6(12): e007724.
PubMed
PubMed Central
Google Scholar
Yang XW, et al. Risk of hypertension with sorafenib use in patients with cancer: a meta-analysis from 20,494 patients. Am J Ther. 2017;24(1):e81–101.
PubMed
Google Scholar
Coppola C, et al. Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev. 2018;63:135–43.
CAS
PubMed
Google Scholar
Arima Y, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 2009;54(3):512–5.
PubMed
Google Scholar
Zhang Y, et al. Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells. Oncol Lett. 2018;15(4):5620–6.
PubMed
PubMed Central
Google Scholar
Lamore SD, et al. Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches. Chem Res Toxicol. 2019;33:125–36.
Google Scholar
Choi HD, Chang MJ. Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis. Breast Cancer Res Treat. 2017;166(3):927–36.
CAS
PubMed
Google Scholar
Chu TF, et al. Cardiotoxicity associated with the tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011.
CAS
PubMed
PubMed Central
Google Scholar
Lee WS, Kim J. Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy. Mol Cell Toxicol. 2018;14(3):247–54.
CAS
Google Scholar
Narayan V, et al. Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2017;23:3601.
CAS
PubMed
PubMed Central
Google Scholar
Long HD, et al. Risk of congestive heart failure in early breast cancer patients undergoing adjuvant treatment with trastuzumab: a meta-analysis. Oncologist. 2016;21:547–54.
CAS
PubMed
PubMed Central
Google Scholar
Kitani T, et al. Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer. Circulation. 2019;139(21):2451–65.
CAS
PubMed
PubMed Central
Google Scholar
Yang L, et al. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells. Int J Oncol. 2017;51:1553–62.
CAS
PubMed
Google Scholar
Watanabe N, Yuasa T, Shimada K. Concurrent administration of trastuzumab and anthracycline for breast cancer treatment: an unassailable contraindication? In: Cardiotoxicity. Rijeka: InTech; 2018.
Google Scholar
Konala VM, Adapa S, Aronow WS. Immune checkpoint inhibitors-related cardiotoxicity. Am J Ther. 2020;27:e591–8.
PubMed
Google Scholar
Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. IJC Heart Vasculature. 2019;25: 100420.
PubMed
PubMed Central
Google Scholar
Oldfield K, et al. Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions. BMJ Case Rep CP. 2021;14: e237217.
Google Scholar
June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73.
CAS
PubMed
PubMed Central
Google Scholar
Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.
CAS
PubMed
PubMed Central
Google Scholar
Ganatra S, et al. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives. J Am Coll Cardiol. 2019;74:3153–63.
CAS
PubMed
PubMed Central
Google Scholar
Davenport AJ, et al. CAR-T cells inflict sequential killing of multiple tumor target cells. Cancer Immunol Res. 2015;3:483–94.
CAS
PubMed
Google Scholar
Park JH, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.
CAS
PubMed
PubMed Central
Google Scholar
Lefebvre B, et al. Cardiovascular effects of CAR T cell therapy: a retrospective study. JACC CardioOncology. 2020;2:193–203.
PubMed
PubMed Central
Google Scholar
Alvi RM, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74:3099–108.
CAS
PubMed
PubMed Central
Google Scholar
Pathan N, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004;363:203–9.
CAS
PubMed
Google Scholar
Strocchio L, et al. Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia. Br J Haematol. 2019;185:360–3.
PubMed
Google Scholar
Alimoghaddam K. A review of arsenic trioxide and acute promyelocytic leukemia. Int J Hematol Oncol Stem Cell Res. 2014;8:44–54.
PubMed
PubMed Central
Google Scholar
Hoonjan M, Jadhav V, Bhatt P. Arsenic trioxide: insights into its evolution to an anticancer agent. J Biol Inorg Chem. 2018;23(3):313–29.
CAS
PubMed
Google Scholar
Westervelt P, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001;98:266–71.
CAS
PubMed
Google Scholar
Alamolhodaei NS, Shirani K, Karimi G. Arsenic cardiotoxicity: an overview. Environ Toxicol Pharmacol. 2015;40:1005–14.
CAS
PubMed
Google Scholar
Wang B, et al. Radiation-induced myocardial fibrosis: mechanisms underlying its pathogenesis and therapeutic strategies. J Cell Mol Med. 2020;24:7717–29.
PubMed
PubMed Central
Google Scholar
Zhuang XF, et al. Late onset radiation-induced constrictive pericarditis and cardiomyopathy after radiotherapy. Medicine. 2017;96: e5932.
PubMed
PubMed Central
Google Scholar
Lee YC, et al. A higher incidence rate of acute coronary syndrome following radiation therapy in patients with breast cancer and a history of coronary artery diseases. Breast Cancer Res Treat. 2015;152:429–35.
PubMed
Google Scholar
Madan R, et al. Radiation induced heart disease: pathogenesis, management and review literature. J Egypt Natl Canc Inst. 2015;27:187–93.
CAS
PubMed
Google Scholar
Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14(7):417–33.
CAS
PubMed
PubMed Central
Google Scholar
Nunes AT, Annunziata CM. Proteasome inhibitors: structure and function. Semin Oncol. 2017;44(6):377–80.
CAS
PubMed
Google Scholar
Rastogi N, Mishra DP. Therapeutic targeting of cancer cell cycle using proteasome inhibitors. Cell Div. 2012;7(1):26.
CAS
PubMed
PubMed Central
Google Scholar
Lee AH, et al. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA. 2003;100(17):9946–51.
CAS
PubMed
PubMed Central
Google Scholar
Wu P, et al. Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management. Curr Oncol Rep. 2020;22(7):66.
PubMed
Google Scholar
Cole DC, Frishman WH. Cardiovascular complications of proteasome inhibitors used in multiple myeloma. Cardiol Rev. 2018;26(3):122–9.
PubMed
Google Scholar
Gurram MK, et al. Cardiotoxicity associated with bortezomib: a single-center experience. J Cancer Res Ther. 2017;13(6):961–3.
PubMed
Google Scholar
Takamatsu H, et al. Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol. 2010;91(5):903–6.
PubMed
Google Scholar
Diwadkar S, Patel AA, Fradley MG. Bortezomib-induced complete heart block and myocardial scar: the potential role of cardiac biomarkers in monitoring cardiotoxicity. Case Rep Cardiol. 2016;2016:3456287.
PubMed
PubMed Central
Google Scholar
Miller Z, et al. Inhibitors of the immunoproteasome: current status and future directions. Curr Pharm Des. 2013;19(22):4140–51.
CAS
PubMed
PubMed Central
Google Scholar
Waxman AJ, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3): e174519.
PubMed
Google Scholar
Jouni H, et al. Ixazomib cardiotoxicity: a possible class effect of proteasome inhibitors. Am J Hematol. 2017;92(2):220–1.
CAS
PubMed
Google Scholar
Amjad MT, Chidharla A, Kasi A. Cancer chemotherapy. In: StatPearls. Treasure Island: StatPearls Publishing LLC; 2021.
Google Scholar
Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263–302.
CAS
PubMed
Google Scholar
Osman M, Elkady M. A prospective study to evaluate the effect of paclitaxel on cardiac ejection fraction. Breast Care. 2017;12(4):255–9.
PubMed
PubMed Central
Google Scholar
Escoto H, Ringewald J, Kalpatthi R. Etoposide-related cardiotoxicity in a child with haemophagocytic lymphohistiocytosis. Cardiol Young. 2010;20(1):105–7.
PubMed
Google Scholar
Wang WT, et al. Noncoding RNAs in cancer therapy resistance and targeted drug development. J Hematol Oncol. 2019;12(1):1–5.
Google Scholar
Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell. 2019;179(5):1033–55.
CAS
PubMed
PubMed Central
Google Scholar
Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2017;18(1):5–18.
PubMed
PubMed Central
Google Scholar
Jaé N, Dimmeler S. Noncoding RNAs in vascular diseases. Circ Res. 2020;126(9):1127–45.
PubMed
Google Scholar
Das S, et al. Noncoding RNAs in cardiovascular disease: current knowledge, tools and technologies for investigation, and future directions: a scientific statement from the American heart association. Circ Genom Precis Med. 2020;13(4): e000062.
PubMed
Google Scholar
Abdellah Z, et al. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931–45.
Google Scholar
Pertea M. The human transcriptome: an unfinished story. Genes. 2012;3(3):344–60.
CAS
PubMed
PubMed Central
Google Scholar
Sauvageau M, et al. Multiple knockout mouse models reveal lincRNAs are required for life and brain development. Elife. 2013;2: e01749.
PubMed
PubMed Central
Google Scholar
Palazzo AF, Lee ES. Non-coding RNA: what is functional and what is junk? Front Genet. 2015;6:2.
PubMed
PubMed Central
Google Scholar
Hobuß L, Bär C, Thum T. Long non-coding RNAs: at the heart of cardiac dysfunction? Front Physiol. 2019. https://doi.org/10.3389/fphys.2019.00030.
Article
PubMed
PubMed Central
Google Scholar
Cabili M, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25(18):1915–27.
CAS
PubMed
PubMed Central
Google Scholar
Derrien T, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.
CAS
PubMed
PubMed Central
Google Scholar
Ma X, Mao M. Optimization selection model and its genetic algorithm for a logistics chain.
Ning Q, et al. The evolution and expression pattern of human overlapping lncRNA and protein-coding gene pairs. Sci Rep. 2017;7(1):1–12.
Google Scholar
Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 2018;24:257–77.
CAS
PubMed
PubMed Central
Google Scholar
Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15:7–21.
CAS
PubMed
Google Scholar
Kim Y-K, Song J. The role of long noncoding RNAs in diabetic Alzheimer’s disease. J Clin Med. 2018;7:461.
CAS
PubMed Central
Google Scholar
Cheng L, et al. Whole blood transcriptomic investigation identifies long non-coding RNAs as regulators in sepsis. J Transl Med. 2020;18:217.
CAS
PubMed
PubMed Central
Google Scholar
Zhu YJ, et al. Peripheral whole blood lncRNA expression analysis in patients with eosinophilic asthma. Medicine. 2018;97: e9817.
CAS
PubMed
PubMed Central
Google Scholar
Du L, et al. Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. J Cell Mol Med. 2018;22:2838–45.
CAS
PubMed
PubMed Central
Google Scholar
Wang J, et al. Circulating lncRNAs as noninvasive biomarkers in bladder cancer: a diagnostic meta-analysis based on 15 published articles. Int J Biol Markers. 2020;35:40–8.
PubMed
Google Scholar
Yousefi H, et al. Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance. Oncogene. 2020;39(5):953–74.
CAS
PubMed
Google Scholar
Wu Y, et al. Advances in the study of exosomal lncRNAs in tumors and the selection of research methods. Biomed Pharmacother. 2020;123: 109716.
CAS
PubMed
Google Scholar
Zhang X, et al. Mechanisms and functions of long non-coding RNAs at multiple regulatory levels. Int J Mol Sci. 2019;20(22):5573.
CAS
PubMed Central
Google Scholar
Statello L, et al. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96–118.
CAS
PubMed
Google Scholar
Bär C, Chatterjee S, Thum T. Long noncoding RNAs in cardiovascular pathology, diagnosis, and therapy. Circulation. 2016;134(19):1484–99.
PubMed
Google Scholar
Tripathi V, et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet. 2013;9: e1003368.
CAS
PubMed
PubMed Central
Google Scholar
Ratti M, et al. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target Oncol. 2020;15(3):261–78.
PubMed
PubMed Central
Google Scholar
Sánchez Y, et al. Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature. Nat Commun. 2014;5(1):1–3.
Google Scholar
Rashid F, Shah A, Shan G. Long non-coding RNAs in the cytoplasm. Genom Proteom Bioinform. 2016;14(2):73–80.
Google Scholar
Hartford CCR, Lal A. When long noncoding becomes protein coding. Mol Cell Biol. 2020;40:e00528-19.
PubMed
PubMed Central
Google Scholar
Xing J, et al. LncRNA-encoded peptide: functions and predicting methods. Front Oncol. 2021. https://doi.org/10.3389/fonc.2020.622294.
Article
PubMed
PubMed Central
Google Scholar
Ye M, et al. Emerging role of long noncoding RNA-encoded micropeptides in cancer. Cancer Cell Int. 2020;20(1):1–9.
CAS
Google Scholar
López-Urrutia E, et al. Crosstalk between long non-coding RNAs, micro-RNAs and mRNAs: deciphering molecular mechanisms of master regulators in cancer. Front Oncol. 2019;9:669.
PubMed
PubMed Central
Google Scholar
Zhang L, et al. Predicting lncRNA–miRNA interactions based on interactome network and graphlet interaction. Genomics. 2021;113:874–80.
CAS
PubMed
Google Scholar
Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA–LncRNA interactions. In: Methods in molecular biology. New York: Humana Press; 2016. p. 271–86.
Google Scholar
Yamamura S, et al. Interaction and cross-talk between non-coding RNAs. Cell Mol Life Sci. 2018;75(3):467–84.
CAS
PubMed
Google Scholar
Fernandes JCR, et al. Long non-coding RNAs in the regulation of gene expression: physiology and disease. Non-coding RNA. 2019;5(1):17.
CAS
PubMed Central
Google Scholar
Sun B, et al. Research progress on the interactions between long non-coding RNAs and microRNAs in human cancer (Review). Oncol Lett. 2020;19:595–605.
CAS
PubMed
Google Scholar
Nakagawa S, Kageyama Y. Nuclear lncRNAs as epigenetic regulators-beyond skepticism. Biochim Biophys Acta Gene Regul Mech. 2014;1839(3):215–22.
CAS
Google Scholar
Kornienko AE, et al. Gene regulation by the act of long non-coding RNA transcription. BMC Biol. 2013;1(1):1–4.
Google Scholar
Guo F, et al. The interplay of LncRNA ANRIL and mir-181b on the inflammation-relevant coronary artery disease through mediating NF-κb signalling pathway. J Cell Mol Med. 2018;22(10):5062–75.
CAS
PubMed
PubMed Central
Google Scholar
Liu X, et al. Long non-coding and coding RNA profiling using strand-specific RNA-seq in human hypertrophic cardiomyopathy. Sci Data. 2019;6(1):1–7.
Google Scholar
Li X, et al. Down-regulation of lncRNA KCNQ1OT1 protects against myocardial ischemia/reperfusion injury following acute myocardial infarction. Biochem Biophys Res Commun. 2017;491(4):1026–33.
CAS
PubMed
Google Scholar
Han D, Gao Q, Cao F. Long noncoding RNAs (LncRNAs)—the dawning of a new treatment for cardiac hypertrophy and heart failure. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2078–84.
CAS
PubMed
Google Scholar
Aung LHH, et al. Cardiomyocyte mitochondrial dynamic-related lncRNA 1 (CMDL-1) may serve as a potential therapeutic target in doxorubicin cardiotoxicity. Mol Ther Nucleic Acids. 2021;25:638–51.
CAS
PubMed
PubMed Central
Google Scholar
Zhang J, et al. Silence of long noncoding RNA NEAT1 inhibits malignant biological behaviors and chemotherapy resistance in gastric cancer. Pathol Oncol Res. 2018;24(1):109–13.
CAS
PubMed
Google Scholar
Sun C, et al. Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway. Oncotarget. 2016;7(32):51784.
PubMed
PubMed Central
Google Scholar
Luo Y, et al. Long non-coding RNA NEAT1 promotes colorectal cancer progression by competitively binding miR-34a with SIRT1 and enhancing the Wnt/β-catenin signaling pathway. Cancer Lett. 2019;440:11–22.
PubMed
Google Scholar
Li Y, et al. LncRNA NEAT1 regulates cell viability and invasion in esophageal squamous cell carcinoma through the miR-129/CTBP2 Axis. Dis Markers. 2017. https://doi.org/10.1155/2017/5314649.
Article
PubMed
PubMed Central
Google Scholar
Koyama S, et al. NEAT1 is required for the expression of the liver cancer stem cell marker CD44. Int J Mol Sci. 2020;21(6):1927.
CAS
PubMed Central
Google Scholar
Ahmed ASI, et al. Long noncoding RNA NEAT1 (nuclear paraspeckle assembly transcript 1) is critical for phenotypic switching of vascular smooth muscle cells. Proc Natl Acad Sci USA. 2018;115(37):E8660–7.
PubMed
PubMed Central
Google Scholar
Du XJ, et al. NEAT1 promotes myocardial ischemia–reperfusion injury via activating the MAPK signaling pathway. J Cell Physiol. 2019;234(10):18773–80.
CAS
PubMed
Google Scholar
Gast M, et al. Long noncoding RNA NEAT1 modulates immune cell functions and is suppressed in early onset myocardial infarction patients. Cardiovasc Res. 2019;115(13):1886–906.
CAS
PubMed
Google Scholar
Wu HJ, et al. Long non-coding RNA NEAT1 modulates hypoxia/reoxygenation-induced cardiomyocyte injury via targeting microRNA-520a. Exp Ther Med. 2019;18(3):2199–2199.
CAS
PubMed
PubMed Central
Google Scholar
Chen XX, et al. Overexpression of the long noncoding RNA NEAT1 protects against As2O3-induced injury of cardiomyocyte by inhibiting the miR-124/NF-κB signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24:1378–90.
PubMed
Google Scholar
Jiang N, et al. TUG1 alleviates hypoxia injury by targeting miR-124 in H9c2 cells. Biomed Pharmacother. 2018;103:1669–77.
CAS
PubMed
Google Scholar
Liu Y, et al. Upregulation of let-7f-2-3p by long noncoding RNA NEAT1 inhibits XPO1-mediated HAX-1 nuclear export in both in vitro and in vivo rodent models of doxorubicin-induced cardiotoxicity. Arch Toxicol. 2019;93(11):3261–76.
CAS
PubMed
Google Scholar
Sheng Z, et al. XPO1-mediated nuclear export of RNF146 protects from angiotensin II-induced endothelial cellular injury. Biochem Biophys Res Commun. 2018;503(3):1544–9.
CAS
PubMed
Google Scholar
Zhuang L, et al. Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p. J Nanobiotechnol. 2020;18(1):1–16.
Google Scholar
Gezer U, et al. Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes. Cell Biol Int. 2014;38(9):1076–9.
CAS
PubMed
Google Scholar
Chen H, Xia W, Hou M. LncRNA-NEAT1 from the competing endogenous RNA network promotes cardioprotective efficacy of mesenchymal stem cell-derived exosomes induced by macrophage migration inhibitory factor via the miR-142-3p/FOXO1 signaling pathway. Stem Cell Res Ther. 2020;11:31.
CAS
PubMed
PubMed Central
Google Scholar
Lellahi SM, et al. The long noncoding RNA NEAT1 and nuclear paraspeckles are up-regulated by the transcription factor HSF1 in the heat shock response. J Biol Chem. 2018;293(49):18965–76.
CAS
PubMed
PubMed Central
Google Scholar
Choudhry H, et al. Tumor hypoxia induces nuclear paraspeckle formation through HIF-2alpha dependent transcriptional activation of NEAT1 leading to cancer cell survival. Oncogene. 2015;34(34):4546.
CAS
PubMed
PubMed Central
Google Scholar
Zhang P, et al. The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun. 2019;10(1):1495.
PubMed
PubMed Central
Google Scholar
Barutcu AR, et al. RUNX1 contributes to higher-order chromatin organization and gene regulation in breast cancer cells. Biochim Biophys Acta. 2016;1859(11):1389–97.
CAS
PubMed
PubMed Central
Google Scholar
Chen Q, et al. Long noncoding RNA NEAT1, regulated by the EGFR pathway, contributes to glioblastoma progression through the WNT/beta-catenin pathway by scaffolding EZH2. Clin Cancer Res. 2018;24(3):684–95.
CAS
PubMed
Google Scholar
Lo PK, et al. Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis. Oncotarget. 2016;7(40):65067–89.
PubMed
PubMed Central
Google Scholar
Fang L, et al. Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VCP-IkappaB. Am J Physiol Gastrointest Liver Physiol. 2017;313(2):G150–6.
PubMed
Google Scholar
Trinklein ND, et al. Transcriptional regulation and binding of heat shock factor 1 and heat shock factor 2 to 32 human heat shock genes during thermal stress and differentiation. Cell Stress Chaperones. 2004;9(1):21–8.
CAS
PubMed
PubMed Central
Google Scholar
Dengler VL, Galbraith M, Espinosa JM. Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol. 2014;49(1):1–15.
CAS
PubMed
Google Scholar
Hong D, et al. RUNX1-dependent mechanisms in biological control and dysregulation in cancer. J Cell Physiol. 2019;234(6):8597–609.
CAS
PubMed
Google Scholar
Nadeau G, et al. BRCA1 can stimulate gene transcription by a unique mechanism. EMBO Rep. 2000;1(3):260–5.
CAS
PubMed
PubMed Central
Google Scholar
Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23–38.
CAS
PubMed
Google Scholar
Zhang Z, et al. A greedy algorithm for aligning DNA sequences. J Comput Biol. 2000;7(1–2):203–14.
CAS
PubMed
Google Scholar
Wang J, et al. KCNQ1OT1 aggravates cell proliferation and migration in bladder cancer through modulating miR-145-5p/PCBP2 axis. Cancer Cell Int. 2019;19(1):1–2.
Google Scholar
Jiang Y, et al. Downregulation of long non-coding RNA Kcnq1ot1: an important mechanism of arsenic trioxide-induced long QT syndrome. Cell Physiol Biochem. 2018;45(1):192–202.
CAS
PubMed
Google Scholar
Wu Y, et al. Long noncoding RNA KCNQ1OT1 is correlated with human breast cancer cell development through inverse regulation of hsa-mir-107. Biochem Cell Biol. 2020;98(3):338–44.
CAS
PubMed
Google Scholar
Zhang S, et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via MIR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018;9(7):1–16.
Google Scholar
Sunamura N, et al. Regulation of functional KCNQ1OT1 lncRNA by beta-catenin. Sci Rep. 2016;6:20690.
CAS
PubMed
PubMed Central
Google Scholar
Lecarpentier Y, et al. Multiple targets of the canonical WNT/beta-catenin signaling in cancers. Front Oncol. 2019;9:1248.
PubMed
PubMed Central
Google Scholar
Shen C, et al. YY1-induced upregulation of lncRNA KCNQ1OT1 regulates angiotensin II-induced atrial fibrillation by modulating miR-384b/CACNA1C axis. Biochem Biophys Res Commun. 2018;505(1):134–40.
CAS
PubMed
Google Scholar
Verheul TCJ, et al. The why of YY1: mechanisms of transcriptional regulation by Yin Yang 1. Front Cell Dev Biol. 2020;8: 592164.
PubMed
PubMed Central
Google Scholar
Li HQ, et al. Obestatin attenuated doxorubicin-induced cardiomyopathy via enhancing long noncoding Mhrt RNA expression. Biomed Pharmacother. 2016;81:474–81.
CAS
PubMed
Google Scholar
Chatterjee S, et al. Noncoding RNAs: potential regulators in cardioncology. Am J Physiol Heart Circ Physiol. 2019;316(1):H160–8.
CAS
PubMed
Google Scholar
Zang H, Mathew RO, Cui T. The dark side of Nrf2 in the Heart. Front Physiol. 2020;11:722.
PubMed
PubMed Central
Google Scholar
Luo Y, et al. The mechanism of myocardial hypertrophy regulated by the interaction between mhrt and myocardin. Cell Signal. 2018;43:11–20.
CAS
PubMed
Google Scholar
Pipes GC, Creemers EE, Olson EN. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev. 2006;20(12):1545–56.
CAS
PubMed
Google Scholar
Cao D, et al. Modulation of smooth muscle gene expression by association of histone acetyltransferases and deacetylases with myocardin. Mol Cell Biol. 2005;25(1):364–76.
CAS
PubMed
PubMed Central
Google Scholar
Zhang CL, Zhu KP, Ma XL. Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett. 2017;396:66–75.
CAS
PubMed
Google Scholar
Venkatesan B, et al. WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death. Cell Signal. 2010;22(5):809–20.
CAS
PubMed
PubMed Central
Google Scholar
Zhang S, et al. LncRNA FOXC2-AS1 protects cardiomyocytes from doxorubicin-induced cardiotoxicity through activation of WNT1-inducible signaling pathway protein-1. Biosci Biotechnol Biochem. 2019;83(4):653–8.
CAS
PubMed
Google Scholar
Wu R, et al. Phenotype-genotype network construction and characterization: a case study of cardiovascular diseases and associated non-coding RNAs. Database J Biol Databases Curation. 2020. https://doi.org/10.1093/database/baz147.
Article
Google Scholar
Zhang N, et al. The long non-coding RNA SNHG1 attenuates cell apoptosis by regulating miR-195 and BCL2-like protein 2 in human cardiomyocytes. Cell Physiol Biochem. 2018;50(3):1029–40.
CAS
PubMed
Google Scholar
Xu M, et al. The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Mol Cancer. 2018;17(1):1–16.
Google Scholar
Xiong X, et al. Long non-coding RNA SNHG1 promotes breast cancer progression by regulation of LMO4. Oncol Rep. 2020;43(5):1503–15.
CAS
PubMed
PubMed Central
Google Scholar
Liu L, et al. The long non-coding RNA SNHG1 promotes glioma progression by competitively binding to miR-194 to regulate PHLDA1 expression. Cell Death Dis. 2019;10(6):1–14.
Google Scholar
Xiao B, et al. The prognostic value of expression of the long noncoding RNA (LncRNA) small nucleolar RNA host gene 1 (SNHG1) in patients with solid malignant tumors: a systematic review and meta-analysis. Med Sci Monit Int Med J Exp Clin Res. 2018;24:5462.
CAS
Google Scholar
Chen S, Wang J, Zhou Y. Long non-coding RNA SNHG1 protects human AC16 cardiomyocytes from doxorubicin toxicity by regulating miR-195/Bcl-2 axis. Biosci Rep. 2019;39:20191050.
Google Scholar
Yu X, et al. SNHG1 represses the anti-cancer roles of baicalein in cervical cancer through regulating miR-3127-5p/FZD4/Wnt/β-catenin signaling. Exp Biol Med. 2021;246(1):20–30.
CAS
Google Scholar
Xu M, et al. The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Mol Cancer. 2018;17(1):141.
PubMed
PubMed Central
Google Scholar
Kang Y, et al. Long noncoding RNA SNHG1 promotes TERT expression by sponging miR-18b-5p in breast cancer. Cell Biosci. 2021;11(1):169.
CAS
PubMed
PubMed Central
Google Scholar
Sahu D, et al. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma. Oncotarget. 2016;7(36):58022–37.
PubMed
PubMed Central
Google Scholar
Li L, et al. Gene regulation by Sp1 and Sp3. Biochem Cell Biol. 2004;82(4):460–71.
CAS
PubMed
Google Scholar
Hsu CL, et al. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data. Oncotarget. 2016;7(24):36293–310.
PubMed
PubMed Central
Google Scholar
Jiang X, et al. Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/lncRNA-SNHG1/miRNA-140–3p/UBE2C axis. Front Cell Dev Biol. 2021;9: 765772.
PubMed
PubMed Central
Google Scholar
Xie Z, Xia W, Hou M. Long intergenic non-coding RNA-p21 mediates cardiac senescence via the Wnt/β-catenin signaling pathway in doxorubicin-induced cardiotoxicity. Mol Med Rep. 2018;17(2):2695–704.
CAS
PubMed
Google Scholar
Xia W, et al. Long-noncoding RNA MALAT1 sponges microRNA-92a-3p to inhibit doxorubicin-induced cardiac senescence by targeting ATG4a. Aging. 2020;12(9):8241.
CAS
PubMed
PubMed Central
Google Scholar
Rogg EM, et al. Analysis of cell type-specific effects of microRNA-92a provides novel insights into target regulation and mechanism of action. Circulation. 2018;138(22):2545–58.
CAS
PubMed
Google Scholar
Singh KK, et al. Autophagy gene fingerprint in human ischemia and reperfusion. J Thorac Cardiovasc Surg. 2014;147(3):1065–72.
CAS
PubMed
Google Scholar
Gutschner T, Hämmerle M, Diederichs S. MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med. 2013;91(7):791–801.
CAS
PubMed
Google Scholar
Gong X, et al. Long noncoding RNA MALAT1 promotes cardiomyocyte apoptosis after myocardial infarction via targeting MIR-144-3p. 2019. Biosci Rep. https://doi.org/10.1042/BSR20191103.
Article
PubMed
PubMed Central
Google Scholar
Cremer S, et al. Hematopoietic deficiency of the long noncoding RNA malat1 promotes atherosclerosis and plaque inflammation. Circulation. 2019;139(10):1320–34.
CAS
PubMed
Google Scholar
Gast M, et al. Immune system-mediated atherosclerosis caused by deficiency of long non-coding RNA MALAT1 in ApoE−/− mice. Cardiovasc Res. 2019;115(2):302–14.
CAS
PubMed
Google Scholar
Tripathi V, et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet. 2013;9(3): e1003368.
CAS
PubMed
PubMed Central
Google Scholar
Liu J-Y, et al. Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis. 2014;5: e1506.
CAS
PubMed
PubMed Central
Google Scholar
Wang G, et al. Association of polymorphisms in MALAT1 with risk of coronary atherosclerotic heart disease in a Chinese population. Lipids Health Dis. 2018;17(1):1–7.
Google Scholar
Li S, et al. Sp1-mediated transcriptional regulation of MALAT1 plays a critical role in tumor. J Cancer Res Clin Oncol. 2015;141(11):1909–20.
CAS
PubMed
Google Scholar
Huang Z, et al. Sp1 cooperates with Sp3 to upregulate MALAT1 expression in human hepatocellular carcinoma. Oncol Rep. 2015;34(5):2403–12.
CAS
PubMed
Google Scholar
Yin BK, Wang ZQ. Beyond HAT adaptor: TRRAP liaisons with Sp1-mediated transcription. Int J Mol Sci. 2021;22(22):12445.
CAS
PubMed
PubMed Central
Google Scholar
Salle-Lefort S, et al. Hypoxia upregulates Malat1 expression through a CaMKK/AMPK/HIF-1alpha axis. Int J Oncol. 2016;49(4):1731–6.
CAS
PubMed
Google Scholar
Luo F, et al. A MALAT1/HIF-2alpha feedback loop contributes to arsenite carcinogenesis. Oncotarget. 2016;7(5):5769–87.
PubMed
Google Scholar
Zhao Y, et al. A novel wnt regulatory axis in endometrioid endometrial cancer. Cancer Res. 2014;74(18):5103–17.
CAS
PubMed
Google Scholar
Sekine H, Motohashi H. Roles of CNC transcription factors NRF1 and NRF2 in cancer. Cancers. 2021;13(3):541.
CAS
PubMed
PubMed Central
Google Scholar
Amodio N, et al. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018;32(9):1948–57.
CAS
PubMed
PubMed Central
Google Scholar
Sun Z, et al. YAP1-induced MALAT1 promotes epithelial–mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer. Oncogene. 2019;38(14):2627–44.
CAS
PubMed
Google Scholar
Krieg AJ, et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol. 2010;30(1):344–53.
CAS
PubMed
Google Scholar
Ohguchi H, et al. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016;7:10258.
CAS
PubMed
PubMed Central
Google Scholar
Ma XY, et al. Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells. BMC Genom. 2015;16:676.
Google Scholar
Kuo IY, et al. Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression. Int J Cancer. 2014;135(3):563–73.
CAS
PubMed
Google Scholar
Zhang Z, et al. Long non-coding RNA UCA1 relieves cardiomyocytes H9c2 injury aroused by oxygen-glucose deprivation via declining miR-122. Artif Cells Nanomed Biotechnol. 2019;47(1):3492–9.
CAS
PubMed
Google Scholar
Shi H, Dong Z, Gao H. LncRNA TUG1 protects against cardiomyocyte ischaemia reperfusion injury by inhibiting HMGB1. Artif Cells Nanomed Biotechnol. 2019;47(1):3511–6.
CAS
PubMed
Google Scholar
Shu L, et al. lncRNA ANRIL protects H9c2 cells against hypoxia-induced injury through targeting the miR-7-5p/SIRT1 axis. J Cell Physiol. 2020;5(1):1–3.
Google Scholar
Xue X, Luo L. LncRNA HIF1A-AS1 contributes to ventricular remodeling after myocardial ischemia/reperfusion injury by adsorption of microRNA-204 to regulating SOCS2 expression. Cell Cycle. 2019;18(19):2465–80.
CAS
PubMed
PubMed Central
Google Scholar
Wang K, et al. CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. Nat Commun. 2014;5(1):1–3.
Google Scholar
Cai B, et al. The long noncoding RNA CAREL controls cardiac regeneration. J Am Coll Cardiol. 2018;72(5):534–50.
PubMed
Google Scholar
Fang J, et al. Investigating the effect of lncRNA HOTAIR on apoptosis induced by myocardial ischemia-reperfusion injury. Mol Med Rep. 2020;23(3):1.
PubMed
PubMed Central
Google Scholar
Wang H, et al. Long noncoding rna sox2-ot aggravates doxorubicin-induced apoptosis of cardiomyocyte by targeting mir-942-5p/dp5. Drug Des Dev Ther. 2021;15:481.
Google Scholar
Shahryari A, et al. Long non-coding RNA SOX2OT: expression signature, splicing patterns, and emerging roles in pluripotency and tumorigenesis. Front Genet. 2015;6:196.
PubMed
PubMed Central
Google Scholar
Knauss JL, et al. Long noncoding RNA Sox2ot and transcription factor YY1 co-regulate the differentiation of cortical neural progenitors by repressing Sox2. Cell Death Dis. 2018;9(8):1–3.
CAS
Google Scholar
Li PY, et al. Long noncoding RNA SOX2-OT: regulations, functions, and roles on mental illnesses, cancers, and diabetic complications. BioMed Res Int. 2020. https://doi.org/10.1155/2020/2901589.
Article
PubMed
PubMed Central
Google Scholar
Wang Y, et al. SOX2OT, a novel tumor-related long non-coding RNA. Biomed Pharmacother. 2020;123: 109725.
CAS
PubMed
Google Scholar
Zhu K, et al. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22. Aging. 2020;12(8):6644–66.
CAS
PubMed
PubMed Central
Google Scholar
Wei CX, et al. IRF4-induced upregulation of lncRNA SOX2-OT promotes cell proliferation and metastasis in cholangiocarcinoma by regulating SOX2 and PI3K/AKT signaling. Eur Rev Med Pharmacol Sci. 2018;22(23):8169–78.
PubMed
Google Scholar
Ochiai K, et al. Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity. 2013;38(5):918–29.
CAS
PubMed
PubMed Central
Google Scholar
Du WW, et al. Foxo3 circular RNApromotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. Eur Heart J. 2017;38(18):1402–12.
CAS
PubMed
Google Scholar
Chen KH, et al. Combined therapy with melatonin and exendin-4 effectively attenuated the deterioration of renal function in rat cardiorenal syndrome. Am J Transl Res. 2017;9(2):214.
CAS
PubMed
PubMed Central
Google Scholar
Wang J, et al. miRNA-regulated delivery of lincRNA-p21 suppresses β-catenin signaling and tumorigenicity of colorectal cancer stem cells. Oncotarget. 2015;6(35):37852.
PubMed
PubMed Central
Google Scholar
Wu G, et al. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation. 2014;130(17):1452–65.
CAS
PubMed
PubMed Central
Google Scholar
Tran UM, et al. LincRNA-p21 acts as a mediator of ING1b-induced apoptosis. Cell Death Dis. 2015;6: e1668.
CAS
PubMed
PubMed Central
Google Scholar
Borges KS, et al. Wnt/beta-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice. Oncogene. 2020;39(30):5282–91.
CAS
PubMed
PubMed Central
Google Scholar
Tell S, et al. The Wnt signaling pathway has tumor suppressor properties in retinoblastoma. Biochem Biophys Res Commun. 2006;349(1):261–9.
CAS
PubMed
Google Scholar
Chen L, et al. Valsartan regulates TGF-β/Smads and TGF-β/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure. Arch Pharm Res. 2018;41(1):101–9.
CAS
PubMed
Google Scholar
Wang K, et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res. 2014;114(9):1377–88.
CAS
PubMed
Google Scholar
Lu Q, et al. lncRNA HOXB-AS3 protects doxorubicin-induced cardiotoxicity by targeting miRNA-875-3p. Exp Ther Med. 2019;19(2):1388–92.
PubMed
PubMed Central
Google Scholar
Zhang XM, et al. LncRNA HOXB-AS3 promotes hepatoma by inhibiting p53 expression. Eur Rev Med Pharmacol Sci. 2018;22(20):6784–92.
PubMed
Google Scholar
Huang JZ, et al. A peptide encoded by a putative lncRNA HOXB-AS3 suppresses colon cancer growth. Mol Cell. 2017;68(1):171–84.
CAS
PubMed
Google Scholar
Huang HH, et al. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer. 2019;19(1):1–14.
Google Scholar
Zhang Y, et al. The long non-coding RNA H19 promotes cardiomyocyte apoptosis in dilated cardiomyopathy. Oncotarget. 2017;8(17):28588–94.
PubMed
PubMed Central
Google Scholar
Liu L, et al. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy. Cardiovasc Res. 2016;111(1):56–65.
CAS
PubMed
Google Scholar
Liu G, et al. Long noncoding RNA H19-derived miR-675 enhances proliferation and invasion via RUNX1 in gastric cancer cells. Oncol Res. 2016;23(3):99–107.
PubMed
PubMed Central
Google Scholar
Li X, et al. LncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy. Sci Rep. 2016;6(1):1–9.
Google Scholar
Berteaux N, et al. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem. 2005;280(33):29625–36.
CAS
PubMed
Google Scholar
Wang Y, et al. The lncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1α. Cell Death Differ. 2020;27(2):695–710.
CAS
PubMed
Google Scholar
Yu Y-H, et al. Cardiac hypertrophy is positively regulated by long non-coding RNA PVT1. Int J Clin Exp Pathol. 2015;8(3):2582–2582.
PubMed
PubMed Central
Google Scholar
Zhan J, Hu P, Wang Y. lncRNA PVT1 aggravates doxorubicin-induced cardiomyocyte apoptosis by targeting the miR-187-3p/AGO1 axis. Mol Cell Probes. 2020;49:101490–101490.
CAS
PubMed
Google Scholar
Sun B, et al. Long noncoding RNA PVT1 contributes to vascular endothelial cell proliferation via inhibition of miR-190a-5p in diagnostic biomarker evaluation of chronic heart failure. Exp Ther Med. 2020;19(5):3348–54.
CAS
PubMed
PubMed Central
Google Scholar
Cao F, et al. LncRNA PVT1 regulates atrial fibrosis via miR-128-3p-SP1-TGF-β1-Smad axis in atrial fibrillation. Mol Med. 2019;25(1):1–11.
CAS
Google Scholar
Wu Y, Xiu W, Wu Y. Salvianolic acid a protects H9C2 cardiomyocytes from doxorubicin-induced damage by inhibiting NFKB1 expression thereby downregulating long-noncoding RNA (lncRNA) plasmacytoma variant translocation 1 (PVT1). Med Sci Monit Int Med J Exp Clin Res. 2021;27:e929824–31.
CAS
Google Scholar
Xu Y, et al. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer. 2019;18(1):141.
PubMed
PubMed Central
Google Scholar
Jia C, et al. Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol. 2019;67:311–8.
CAS
PubMed
Google Scholar
Tavakoli Dargani Z, et al. Exosomes derived from embryonic stem cells inhibit doxorubicin and inflammation-induced pyroptosis in muscle cells. Can J Physiol Pharmacol. 2018;96(3):304–7.
CAS
PubMed
Google Scholar
Wei S, et al. Involvement of ROS/NLRP3 inflammasome signaling pathway in doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2020;20(5):507–19.
CAS
PubMed
Google Scholar
Meng L, et al. Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3. J Mol Cell Cardiol. 2019;136:15–26.
CAS
PubMed
Google Scholar
Weidensdorfer D, et al. Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. RNA. 2009;15(1):104–104.
CAS
PubMed
PubMed Central
Google Scholar
Wang Q, et al. LncRNA TINCR favors tumorigenesis via STAT3-TINCR-EGFR-feedback loop by recruiting DNMT1 and acting as a competing endogenous RNA in human breast cancer. Cell Death Dis. 2021;12(1):83.
PubMed
PubMed Central
Google Scholar
Stoskus M, Eidukaite A, Griskevicius L. Defining the significance of IGF2BP1 overexpression in t(12;21)(p13;q22)-positive leukemia REH cells. Leuk Res. 2016;47:16–21.
CAS
PubMed
Google Scholar
Jiang Q, et al. Role of Stat3 in NLRP3/caspase-1-mediated hippocampal neuronal pyroptosis in epileptic mice. Synapse. 2021. https://doi.org/10.1002/syn.22221.
Article
PubMed
Google Scholar
Li J, et al. Long noncoding RNA LINC00339 aggravates doxorubicin-induced cardiomyocyte apoptosis by targeting MiR-484. Biochem Biophys Res Commun. 2018;503(4):3038–43.
CAS
PubMed
Google Scholar
Zou L, et al. Long noncoding RNA-MEG3 contributes to myocardial ischemia–reperfusion injury through suppression of MIR-7-5p expression. 2019. Biosci Rep. https://doi.org/10.1042/BSR20190210.
Article
PubMed
PubMed Central
Google Scholar
Liang H, et al. LncRNA PFL contributes to cardiac fibrosis by acting as a competing endogenous RNA of let-7d. Theranostics. 2018;8(4):1180–1180.
CAS
PubMed
PubMed Central
Google Scholar
Ha T-Y. MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw. 2011;11(3):135–54.
PubMed
PubMed Central
Google Scholar
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
CAS
PubMed
Google Scholar
Chen X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.
CAS
PubMed
Google Scholar
Gu W, et al. The role of RNA structure at 5′ untranslated region in microRNA-mediated gene regulation. RNA. 2014;20(9):1369–75.
CAS
PubMed
PubMed Central
Google Scholar
Perera RJ, Ray A. MicroRNAs in the search for understanding human diseases. BioDrugs. 2007;21(2):97–104.
CAS
PubMed
Google Scholar
Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28(3):369–78.
CAS
PubMed
Google Scholar
Zhang WB, Lai X, Guo XF. Activation of Nrf2 by miR-152 inhibits doxorubicin-induced cardiotoxicity via attenuation of oxidative stress, inflammation, and apoptosis. Oxid Med Cell Longev. 2021. https://doi.org/10.1155/2021/8860883.
Article
PubMed
PubMed Central
Google Scholar
LaRocca TJ, et al. Pharmacological silencing of miR-152 prevents pressure overload-induced heart failure. Circ Heart Fail. 2020;13(3):e006298–e006298.
CAS
PubMed
PubMed Central
Google Scholar
Wang X, et al. TLR3 mediates repair and regeneration of damaged neonatal heart through glycolysis dependent YAP1 regulated miR-152 expression. Cell Death Differ. 2018;25(5):966–966.
CAS
PubMed
PubMed Central
Google Scholar
Li N, Zhou H, Tang Q. miR-133: a suppressor of cardiac remodeling? Front Pharmacol. 2018. https://doi.org/10.3389/fphar.2018.00903.
Article
PubMed
PubMed Central
Google Scholar
Wang Y, et al. Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy. Mol Med Rep. 2017;15(1):359–65.
CAS
PubMed
Google Scholar
Cortez-Dias N, et al. Circulating miR-122-5p/miR-133B ratio is a specific early prognostic biomarker in acute myocardial infarction. Circ J. 2016;80(10):2183–91.
CAS
PubMed
Google Scholar
Chen J, et al. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling. J Biochem Mol Toxicol. 2020;34(4): e22452.
CAS
PubMed
Google Scholar
Atef MM, et al. Long non-coding RNA EGFR-AS1 in colorectal cancer: potential role in tumorigenesis and survival via miRNA-133b sponge and EGFR/STAT3 axis regulation. Br J Biomed Sci. 2021;78(3):122–9.
CAS
PubMed
Google Scholar
Sandhu H, et al. Attenuation of sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation. Eur J Pharmacol. 2017;814:95–105.
CAS
PubMed
Google Scholar
Hanousková B, et al. Imatinib-induced changes in the expression profile of microRNA in the plasma and heart of mice—a comparison with doxorubicin. Biomed Pharmacother. 2019;115: 108883.
PubMed
Google Scholar
Panizo S, et al. Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis. Nephrol Dial Transplant. 2017;32(11):1831–40.
CAS
PubMed
Google Scholar
Roca-Alonso L, et al. Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis. Cell Death Dis. 2015;6(5): e1754.
CAS
PubMed
PubMed Central
Google Scholar
Li Z, et al. MicroRNA-133b alleviates doxorubicin-induced cardiomyocyte apoptosis and cardiac fibrosis by targeting PTBP1 and TAGLN2. Int J Mol Med. 2021;48(1):1–11.
CAS
Google Scholar
Pan Y, et al. MicroRNA-98 ameliorates doxorubicin-induced cardiotoxicity via regulating caspase-8 dependent Fas/RIP3 pathway. Environ Toxicol Pharmacol. 2021;85:103624–103624.
CAS
PubMed
Google Scholar
Zhang T, et al. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med. 2016;22(2):175–82.
PubMed
Google Scholar
Sun C, et al. MicroRNA-98 negatively regulates myocardial infarction-induced apoptosis by down-regulating Fas and caspase-3. Sci Rep. 2017;7(1):1–11.
Google Scholar
Ma W, et al. Pre-treatment with melatonin enhances therapeutic efficacy of cardiac progenitor cells for myocardial infarction. Cell Physiol Biochem. 2018;47(3):1287–98.
CAS
PubMed
Google Scholar
Dai Y, et al. MicroRNA-98 regulates foam cell formation and lipid accumulation through repression of LOX-1. Redox Biol. 2018;16:255–62.
CAS
PubMed
PubMed Central
Google Scholar
Cheng R, et al. MicroRNA-98 inhibits TGF-β1-induced differentiation and collagen production of cardiac fibroblasts by targeting TGFBR1. Hum Cell. 2017;30(3):192–200.
CAS
PubMed
Google Scholar
Zhai C-L, et al. MicroRNA-98 attenuates cardiac ischemia-reperfusion injury through inhibiting DAPK1 expression. IUBMB Life. 2019;71(2):166–76.
CAS
PubMed
Google Scholar
Wan Q, et al. miR-499-5p attenuates mitochondrial fission and cell apoptosis via p21 in doxorubicin cardiotoxicity. Front Genet. 2019;9(JAN):734–734.
PubMed
PubMed Central
Google Scholar
Van Rooij E, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA. 2008;105(35):13027–32.
PubMed
PubMed Central
Google Scholar
Li Z, et al. MicroRNA-29 regulates myocardial microvascular endothelial cells proliferation and migration in association with IGF1 in type 2 diabetes. Biochem Biophys Res Commun. 2017;487(1):15–21.
CAS
PubMed
Google Scholar
Chen HX, et al. MicroRNA-29b inhibits angiogenesis by targeting VEGFA through the MAPK/ERK and PI3K/Akt signaling pathways in endometrial carcinoma. Cell Physiol Biochem. 2017;41(3):933–46.
CAS
PubMed
Google Scholar
Jing X, et al. MicroRNA-29b regulates the mitochondria-dependent apoptotic pathway by targeting bax in doxorubicin cardiotoxicity. Cell Physiol Biochem. 2018;48(2):692–704.
CAS
PubMed
Google Scholar
Dinh TKT, et al. Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer. Radiat Oncol. 2016;11(1):1–11.
Google Scholar
Xu W, et al. MiR-29 family inhibits resistance to methotrexate and promotes cell apoptosis by targeting COL3A1 and MCL1 in osteosarcoma. Med Sci Monit. 2018;24:8812.
CAS
PubMed
PubMed Central
Google Scholar
Choghaei E, et al. Knockdown of microRNA-29a changes the expression of heat shock proteins in breast carcinoma MCF-7 cells. Oncol Res. 2016;23(1–2):69.
PubMed
PubMed Central
Google Scholar
Xiong X, et al. MicroRNA miR-215-5p regulates doxorubicin-induced cardiomyocyte injury by targeting ZEB2. J Cardiovasc Pharmacol. 2021;78(4):622–9.
CAS
PubMed
Google Scholar
Desai VG, et al. Early biomarkers of doxorubicin-induced heart injury in a mouse model. Toxicol Appl Pharmacol. 2014;281(2):221–9.
CAS
PubMed
Google Scholar
Machackova T, et al. MiR-215-5p reduces liver metastasis in an experimental model of colorectal cancer through regulation of ECM-receptor interactions and focal adhesion. Cancers. 2020;12(12):3518.
CAS
PubMed Central
Google Scholar
Pellegrini L, et al. MicroRNAs in cancer treatment-induced cardiotoxicity. Cancers. 2020;12(3):704.
CAS
PubMed Central
Google Scholar
Carlomosti F, et al. Oxidative stress-induced miR-200c disrupts the regulatory loop among SIRT1, FOXO1, and eNOS. Antioxid Redox Signal. 2017;27(6):328–44.
CAS
PubMed
Google Scholar
Beji S, et al. Doxorubicin upregulates CXCR4 via miR-200c/ZEB1-dependent mechanism in human cardiac mesenchymal progenitor cells. Cell Death Dis. 2017;8(8): e3020.
CAS
PubMed
PubMed Central
Google Scholar
Xu C, Liu CH, Zhang DL. MicroRNA-22 inhibition prevents doxorubicin-induced cardiotoxicity via upregulating SIRT1. Biochem Biophys Res Commun. 2020;521(2):485–91.
CAS
PubMed
Google Scholar
Song N, et al. USP7 deubiquitinates and stabilizes SIRT1. Anat Rec. 2020;303(5):1337–45.
CAS
Google Scholar
Zhu JN, et al. Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity. Sci Rep. 2017;7(1):1–12.
Google Scholar
Caon I, et al. Sirtuin 1 reduces hyaluronan synthase 2 expression by inhibiting nuclear translocation of NF-κB and expression of the long-noncoding RNA HAS2–AS1. J Biol Chem. 2020;295(11):3485–96.
CAS
PubMed
PubMed Central
Google Scholar
Kim YH, et al. Endothelial glycocalyx as biomarker for cardiovascular diseases: mechanistic and clinical implications. Curr Heart Fail Rep. 2017;14(2):117–26.
CAS
PubMed
PubMed Central
Google Scholar
Lacombe J, Zenhausern F. Emergence of miR-34a in radiation therapy. Crit Rev Oncol Hematol. 2017;109:69–78.
PubMed
Google Scholar
Shan H, et al. Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling. Int J Cardiol. 2013;167(6):2798–805.
PubMed
Google Scholar
Yin Z, et al. miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway. Aging. 2016;8:192–207.
CAS
PubMed
PubMed Central
Google Scholar
Zhang L, Liu L, Li X. MiR-526b-3p mediates doxorubicin-induced cardiotoxicity by targeting STAT3 to inactivate VEGFA. Biomed Pharmacother. 2020;123: 109751.
CAS
PubMed
Google Scholar
Du J, et al. Inhibition of miR-23a attenuates doxorubicin-induced mitochondria-dependent cardiomyocyte apoptosis by targeting the PGC-1α/Drp1 pathway. Toxicol Appl Pharmacol. 2019;369:73–81.
CAS
PubMed
Google Scholar
Ahkin Chin Tai JK, Freeman JL. Zebrafish as an integrative vertebrate model to identify miRNA mechanisms regulating toxicity. Toxicol Rep. 2020;7:559–70.
CAS
PubMed
PubMed Central
Google Scholar
Guo J, et al. Cardioprotection against doxorubicin by metallothionein is associated with preservation of mitochondrial biogenesis involving PGC-1α pathway. Eur J Pharmacol. 2014;737:117–24.
CAS
PubMed
Google Scholar
Chistiakov DA, et al. Human miR-221/222 in physiological and atherosclerotic vascular remodeling. Biomed Res Int. 2015. https://doi.org/10.1155/2015/354517.
Article
PubMed
PubMed Central
Google Scholar
Sun LL, et al. The regulatory role of microRNAs in angiogenesis-related diseases. J Cell Mol Med. 2018;22(10):4568–87.
CAS
PubMed
PubMed Central
Google Scholar
Poliseno L, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood. 2006;108(9):3068–71.
CAS
PubMed
Google Scholar
Liu X, et al. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res. 2009;104(4):476–87.
CAS
PubMed
PubMed Central
Google Scholar
Celic T, et al. The mir-221/222 cluster is a key player in vascular biology via the fine-tuning of endothelial cell physiology. Curr Vasc Pharmacol. 2016;15(1):40–6.
Google Scholar
Verjans R, et al. MicroRNA-221/222 family counteracts myocardial fibrosis in pressure overload-induced heart failure. Hypertension. 2018;71(2):280–8.
CAS
PubMed
Google Scholar
Jain D, et al. Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions. Curr Cardiol Rep. 2017;19(5):1–2.
Google Scholar
Tahover E, et al. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival. Anticancer Drugs. 2017;28:787–94.
CAS
PubMed
Google Scholar
Maruyama R, Yokota T. Knocking down long noncoding RNAs using antisense oligonucleotide gapmers. In: Methods in molecular biology. Humana Press Inc: New York; 2020. p. 49–56.
Google Scholar
Wu P. Inhibition of RNA-binding proteins with small molecules. Nat Rev Chem. 2020;4:441–58.
CAS
Google Scholar
Phelan JD, Staudt LM. CRISPR-based technology to silence the expression of IncRNAs. Proc Natl Acad Sci USA. 2020;117(15):8225–7.
CAS
PubMed
PubMed Central
Google Scholar
Gao F, et al. Reverse-genetics studies of lncRNAs-what we have learnt and paths forward. Genome Biol. 2020;21:1–23.
Google Scholar
Ruan X, et al. In vivo functional analysis of non-conserved human lncRNAs associated with cardiometabolic traits. Nat Commun. 2020;11:1–13.
Google Scholar
Kern C, et al. Genome-wide identification of tissue-specific long non-coding RNA in three farm animal species. BMC Genom. 2018;19:1–14.
Google Scholar
Urits I, et al. A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther. 2020;9:1–15.
Google Scholar
Pian C, et al. LncCeRBase: a database of experimentally validated human competing endogenous long non-coding RNAs. Database. 2018. https://doi.org/10.1093/database/bay061.
Article
PubMed
PubMed Central
Google Scholar
Miao YR, et al. lncRNASNP2: an updated database of functional SNPs and mutations in human and mouse lncRNAs. Nucleic Acids Res. 2018;46(D1):D276–80.
CAS
PubMed
Google Scholar
Karagkouni D, et al. DIANA-LncBase v3: indexing experimentally supported miRNA targets on non-coding transcripts. Nucleic Acids Res. 2020;48(D1):D101–10.
CAS
PubMed
Google Scholar
Yang S, et al. LncMirNet: predicting LncRNA-miRNA interaction based on deep learning of ribonucleic acid sequences. Molecules. 2020;25(19):4372.
CAS
PubMed Central
Google Scholar
Das S, et al. lnCeDB: database of human long noncoding RNA acting as competing endogenous RNA. PLoS ONE. 2014;9(6): e98965.
PubMed
PubMed Central
Google Scholar
Bhattacharya A, Cui Y. SomamiR 2.0: a database of cancer somatic mutations altering microRNA-ceRNA interactions. Nucleic Acids Res. 2016;44(D1):D1005–10.
CAS
PubMed
Google Scholar
Wang P, et al. miRSponge: a manually curated database for experimentally supported miRNA sponges and ceRNAs. Database. 2015. https://doi.org/10.1093/database/bav098.
Article
PubMed
PubMed Central
Google Scholar
Li JH, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(Database issue):D92–7.
CAS
PubMed
Google Scholar
Lu Q, et al. lncRNA HOXB-AS3 protects doxorubicin-induced cardiotoxicity by targeting miRNA-875-3p. Exp Ther Med. 2019;19:1388–92.
PubMed
PubMed Central
Google Scholar
Xie Z, Xia W, Hou M. Long intergenic non-coding RNA-p21 mediates cardiac senescence via the Wnt/β-catenin signaling pathway in doxorubicin-induced cardiotoxicity. Mol Med Rep. 2018;17:2695–704.
CAS
PubMed
Google Scholar
Zhang S, et al. LncRNA FOXC2-AS1 protects cardiomyocytes from doxorubicin-induced cardiotoxicity through activation of WNT1-inducible signaling pathway protein-1. Biosci Biotechnol Biochem. 2019;83:653–8.
CAS
PubMed
Google Scholar
Zhan J, Hu P, Wang Y. lncRNA PVT1 aggravates doxorubicin-induced cardiomyocyte apoptosis by targeting the miR-187-3p/AGO1 axis. Mol Cell Probes. 2020;49: 101490.
CAS
PubMed
Google Scholar
Jiang Y, et al. Downregulation of long non-coding RNA Kcnq1ot1: an important mechanism of arsenic trioxide-induced long QT syndrome. Cell Physiol Biochem. 2018;45:192–202.
CAS
PubMed
Google Scholar
Chen S, Wang J, Zhou Y. Long non-coding RNA SNHG1 protects human AC16 cardiomyocytes from doxorubicin toxicity by regulating miR-195/Bcl-2 axis. 2019. Biosci Rep. https://doi.org/10.1042/BSR20191050.
Article
PubMed
PubMed Central
Google Scholar
Li J, et al. Long noncoding RNA LINC00339 aggravates doxorubicin-induced cardiomyocyte apoptosis by targeting MiR-484. Biochem Biophys Res Commun. 2018;503:3038–43.
CAS
PubMed
Google Scholar
Pan Y, et al. MicroRNA-98 ameliorates doxorubicin-induced cardiotoxicity via regulating caspase-8 dependent Fas/RIP3 pathway. Environ Toxicol Pharmacol. 2021;85: 103624.
CAS
PubMed
Google Scholar
Wan Q, et al. miR-499-5p attenuates mitochondrial fission and cell apoptosis via p21 in doxorubicin cardiotoxicity. Front Genet. 2019;9:734.
PubMed
PubMed Central
Google Scholar
Xu C, Liu CH, Zhang DL. MicroRNA-22 inhibition prevents doxorubicin-induced cardiotoxicity via upregulating SIRT1. Biochem Biophys Res Commun. 2020;521:485–91.
CAS
PubMed
Google Scholar